News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Madrid's IBEX 35 fell 1.45% to a three-month low as banks and renewables led declines.
  • Helsinki's OMX Helsinki 25 closed lower as Basic Materials, Oil & Gas and Utilities weighed on the index.
  • Stockholm's OMX Stockholm 30 rose 0.33% led by Healthcare, Financials and Technology gains.
  • Milan's Italy 40 climbed 0.39% with Travel, Chemicals and Oil & Gas among the top performers.
  • Germany's DAX gained 0.42% to a one-month high as technology, food and utilities outperformed.
  • Commodities and FX were mixed across sessions, with crude and Brent rising while gold eased and the dollar softened.

Latest Articles

Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand

Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand

Tilray Brands, Inc. has significantly expanded its global medical cannabis cultivation capacity from 210 to approximately 275 metric tonnes annually, enhancing supply from its Quebec and EU-GMP-certified Portugal facilities. This expansion strengthens Tilray's leadership in key international medical cannabis markets including Canada, Europe, Austra…

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

NovaBridge Biosciences reported its first half 2026 financial results showing increased R&D and administrative expenses reflecting advancement of its pipeline. The company announced key clinical milestones including plans to start a registrational Phase 3 study of givastomig by year-end 2026 under a potential FDA Accelerated Approval Pathway and pr…

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Pharma Ltd. announced a strategic collaboration and equity investment in IntraGel Therapeutics to access its proprietary biodegradable sustained-release gel platform (SRGel). This agreement grants UroGen research licensing and exclusive options to develop up to three novel oncology products, along with an exclusive option to commercialize Tu…

ARRAY Technologies to Detail Balance-of-System Strategy and APA Long-Term Growth Opportunities at the APA Investor Technology Showcase Today

ARRAY Technologies to Detail Balance-of-System Strategy and APA Long-Term Growth Opportunities at the APA Investor Technology Showcase Today

ARRAY Technologies held its APA Investor Technology Showcase to detail its strategy to evolve from a tracker-only company into a fully integrated energy infrastructure platform, highlighting progress with APA Solar integration, growth opportunities, and the pending acquisition of Affordable Wire Management to expand into solar infrastructure compon…

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Fractyl Health announced a virtual Commercial Strategy Day for September 1, 2026, to discuss the commercialization potential and go-to-market plan for Revita®, their procedural therapy designed to maintain weight loss after GLP-1 treatment cessation. This follows encouraging one-year data showing significant weight maintenance after a single Revita…

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion, Inc. announces the University of Arizona College of Medicine – Phoenix as a new clinical site in its ongoing CLARITY trial, a pivotal multi-center study evaluating Nociscan's ability to identify painful spinal discs and improve outcomes in patients undergoing surgery for chronic low back pain. The addition of this prominent neurosurgery a…

Parsons Selected for $350M Seabed to Space ISR Effort

Parsons Selected for $350M Seabed to Space ISR Effort

Parsons Corporation secured a $350 million IDIQ contract from Naval Information Warfare Center Pacific to provide full lifecycle engineering and technical services for the Seabed to Space Intelligence Surveillance Reconnaissance program. This contract supports development, deployment, and sustainment of ISR systems across maritime, air, land, and s…

AIR Global Reports 2026 First-Half Results

AIR Global Reports 2026 First-Half Results

AIR Global PLC reported a 3.7% revenue increase to $206.9 million in the first half of 2026 despite supply chain disruptions from the Strait of Hormuz closure. Adjusted EBITDA remained stable at $71.7 million year-over-year. However, the company posted a net loss of $81.8 million largely due to one-time IPO-related expenses and costs associated wit…